June 29, 2021 ~ TrialSite News ~
Swedish-Anglo Study in Turkey Reveals Metabolic Activators Reduce COVID-19 Duration by 3.5 Days—Now Submission for Approval in Turkey
A group of Swedish, English and Turkish researchers found that the use of metabolic activators can reduce COVID-19 recovery time by as much as 3.5 days in those patients with mild-to-moderate forms of the infection. The Swedish-Anglo study published in Advanced Science also indicated benefits associated with inflammation level of the liver as revealed by inflammatory markers. Led by investigators at Science for Life Laboratory at KTH Royal Institute of Technology in Stockholm, the study team collaborated with another Swedish group called the Sahlgrenska Academy based in Gothenburg as well as King’s College, London, where a Phase 3 clinical trial reveals that patients with mild-to-moderate COVID-19—that is, those cases representing the overwhelming majority of COVID-19 cases—who also received standard of care, experienced overall a 3.5-day reduction in recovery time when receiving the combination of metabolic activators, nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate. All four of these activators are aimed at improving mitochondrial function. These results build upon the positive findings of Phase 2 clinical data, report the authors in a recent press release. The Phase 3 study was actually conducted at the Umraniye Teaching and Research Hospital, University of Health Sciences in Istanbul. Now thanks to these results, the combination therapy was submitted for marketing authorization in Turkey.